0001209191-23-046905.txt : 20230822
0001209191-23-046905.hdr.sgml : 20230822
20230822163153
ACCESSION NUMBER: 0001209191-23-046905
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230821
FILED AS OF DATE: 20230822
DATE AS OF CHANGE: 20230822
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Monahan Joseph
CENTRAL INDEX KEY: 0001861790
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37581
FILM NUMBER: 231193936
MAIL ADDRESS:
STREET 1: C/O ACLARIS THERAPEUTICS, INC.
STREET 2: 640 LEE ROAD, SUITE 200
CITY: WAYNE
STATE: PA
ZIP: 19087
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc.
CENTRAL INDEX KEY: 0001557746
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 460571712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 640 LEE ROAD
STREET 2: SUITE 200
CITY: WAYNE
STATE: PA
ZIP: 19087
BUSINESS PHONE: 484-324-7933
MAIL ADDRESS:
STREET 1: 640 LEE ROAD
STREET 2: SUITE 200
CITY: WAYNE
STATE: PA
ZIP: 19087
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-08-21
0
0001557746
Aclaris Therapeutics, Inc.
ACRS
0001861790
Monahan Joseph
C/O ACLARIS THERAPEUTICS, INC.
640 LEE ROAD, SUITE 200
WAYNE
PA
19087
0
1
0
0
Chief Scientific Officer
1
Common Stock
2023-08-21
4
S
0
6000
7.3158
D
135724
D
Common Stock
193
I
By Spouse
These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2023.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $7.18 to $7.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Mark Ballantyne, Attorney-in-fact
2023-08-22